U.S.-China public hearing
This article was originally published in The Tan Sheet
Executive Summary
The U.S.-China Economic and Security Review Commission will hold a public hearing "to examine contemporary developments in Chinese information control mechanisms, the factors motivating those systems and the impact they have on America's ability to assure the safety of Chinese imports," according to a July 18 Federal Register notice. The hearing, entitled "Access to Information in the People's Republic of China," will be held from 9 a.m. till 4:30 p.m. in the Russell Senate Office Building on Capitol Hill July 31, the Commission states...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.